Bon Natural Life Limited — FY2021 Form 20-F
Reporting period: Fiscal year ended September 30, 2021; this is an annual report, not a standalone 2021 Q4 report. The company is a China-based natural ingredients and health-products business, reporting in U.S. dollars under U.S. GAAP. Financial statements received an unqualified audit opinion from Friedman LLP.
Financial performance and position
| Metric | FY2021 / September 30, 2021 | Prior comparable period |
|---|---|---|
| Revenue | $25.49 million | $18.22 million; up 39.9% |
| Gross profit / margin | $7.11 million / 27.9% | $5.20 million / 28.6% |
| Operating income / margin | $5.40 million / 21.2% | $3.47 million / 19.0% |
| Net income | $4.61 million; attributable to Bon Natural Life: $4.59 million | $3.10 million; attributable: $3.03 million |
| Basic / diluted EPS | $0.69 / $0.68 | $0.58 / $0.58 |
| Operating cash flow | $4.05 million | $2.64 million |
| Cash and short-term investments | $1.90 million and $1.70 million | Cash: $0.05 million; no short-term investments reported |
| Total assets / liabilities / equity | $36.41 million / $9.88 million / $26.53 million | $25.20 million / $14.18 million / $11.02 million |
At year-end, current assets were $16.55 million and current liabilities $7.53 million. Borrowings totaled approximately $2.66 million, excluding lease liabilities. Investing cash outflow was $7.44 million, primarily for plant construction, short-term investments and an acquisition-related deposit; financing cash inflow was $5.35 million, including $11.27 million of net IPO proceeds. Management said approximately $6.15 million of year-end receivables had been collected by the filing date.
Changes versus FY2020
- Revenue rose 39.9%; fragrance compounds increased 61.7% to $12.74 million, and health supplement powder drinks increased 71.2% to $6.66 million. Bioactive food ingredient revenue fell 5.6% to $6.09 million.
- Growth reflected higher prices and volumes in fragrance and powder drinks, more customers, and a favorable currency translation effect. Bioactive ingredient demand—especially for stachyose—eased after pandemic-related demand in FY2020.
- Gross profit increased 36.7%, but gross margin contracted 0.7 percentage point to 27.9%, reflecting product mix and higher raw-material costs. Operating expenses declined slightly to $1.71 million; operating margin improved.
- Net income grew 48.8%. Net cash from operations also improved, while capital spending remained substantial. Year-end current liabilities declined, in part as bank and related-party borrowings were repaid; taxes payable remained elevated.
Outlook, risks and unusual items
- Expansion: Management targets at least 30% compound annual growth in its raw materials and ingredients business over the next two to three years. It plans to expand production, R&D, marketing and distribution. This is a management target, not guaranteed guidance.
- Capital commitments: Two manufacturing projects had approximately $5.1 million of remaining capital commitments at September 30, 2021, including about $2.3 million due within 12 months. The Tongchuan project budget had increased to approximately $17.7 million; completion was expected by December 2022. The Yumen project budget was approximately $6.2 million, with completion expected around October 2022.
- Liquidity and taxes: The company reported approximately $5.1 million in taxes payable at year-end, including about $3.3 million VAT and $1.7 million income tax. Authorities extended settlement to June 30, 2022 without interest or penalties during the extension. Management expected available cash, short-term investments, operating cash flow and unused credit facilities to cover at least 12 months from issuance of the financial statements.
- COVID-19: FY2021 results benefited from resumed operations and increased orders, but the filing warns that renewed outbreaks could disrupt production, supply, deliveries, collections and cash flows.
- Corporate structure: The company terminated its VIE arrangements effective November 1, 2021 and moved to indirect equity ownership of Xi’an App-Chem through PRC wholly foreign-owned subsidiaries. Its online-sales license was revoked and online sales were outsourced to a licensed third party. Management said the restructuring did not change control; PRC regulatory interpretation and potential retrospective consequences remain uncertain.
- Other material risks: Customer and supplier concentration (two customers represented 61.6% of FY2021 revenue); product safety and efficacy claims without company-sponsored clinical trials; PRC regulatory, foreign-exchange and dividend-transfer risks; construction, lease and permit compliance; competition; and currency exposure. The filing also discloses material weaknesses in financial reporting controls, including insufficient U.S. GAAP/SEC expertise and documented close procedures. Management concluded controls were ineffective at September 30, 2021 and had not fully remedied the weaknesses.
- Unusual items: FY2021 included $449,972 of government subsidies. The company completed a $12.65 million gross IPO in June–July 2021. A $1 million consulting/acquisition deposit was refundable under stated conditions. No material litigation or off-balance-sheet arrangements were reported; the company did not expect to pay dividends in the foreseeable future.
Important facts for investors to verify
- Whether the $5.1 million tax balance was settled by the extended June 30, 2022 deadline and whether any additional tax, interest or penalties arose.
- Progress, total cost, funding and commissioning of the Tongchuan and Yumen plants, including whether planned capacity and customer demand materialized.
- Whether customer concentration and receivable concentration remain high, and whether the FY2021 customer orders and collections were sustained.
- Whether internal-control remediation was completed and whether subsequent filings report any additional weaknesses or audit adjustments.
- Current status and regulatory compliance of the post-VIE ownership structure, overseas listing requirements, and the replacement online-sales arrangements.